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Abstract Background:Alpha-1-antitrypsin (AT) deficiencyis a hereditarydisorder associatedwithpulmonary emphy-
sema. ATreplacementtherapy has been available formany years with only one randomised controlled trial, showing no
improvement intherate ofdecline in lung function.We aimedto obtain furtherdata onthenaturalhistoryofthe disorder
and thus to refine the criteria for future clinical trials.Methods:Homozygotes for Pi type Zwere identified among chest
clinic patients and close relatives.Clinical and lung function datawere obtainedbymeans of a standardised questionnaire
administered yearly for a maximum of 15 years. Results:Baseline study: forced expiratory volume in 1s (FEV1) and vital
capacity (VC) were studied in194 Pi type Z patients at registration. Past or present smoking history had the strongest
relationshiptoreductionin FEV1 (Po0.001), but amongthosewhohadsmoked, estimatedtotallifetimetobaccoconsump-
tion (kg)wasnot significantlyrelatedto FEV1.No effecton FEV1wasproducedbygender, ageof starting to smoke, asthma,
occupationorintra-family factorsinsibpairsconcordantfor smoking.Follow-upstudy:In 71patients, theaveragenumberof
annuallung function assessments per subject was 8.0 (range 6 --13) and average follow-uptime 9.7 years (range 4.2--14.9).
FEV1slope tendedto be steeper in current smokers thanin ex-smokers (0.05oPo0.1) andgreatest inpatientswithinitial
FEV1inthe range 30--65% predicted.Effects onVCwere less severe.Much deteriorationtakesplace before emphysema-
tous patients come to clinical attention. FEV1 slopes calculated using only the first four assessments have a significantly
greater variancethanwhencalculatedonall assessments (F=3.79;Po0.01).FEV1andVCslopesusingpost-bronchodilator
values are greater thanwhenusing pre-bronchodilator values.Conclusions:Future trials of ATreplacementtherapyneed
rigorous standardisationof lung functiontesting (includingbronchodilatorprotocol) togetherwith an adequateperiodof
assessment.Only randomised controlled trials should be considered valid.Therapy should ideally be started earlier than
normallyenvisaged andbefore the onsetof clinical emphysema.r2002 Elsevier Science Ltd.Allrightsreserved.
Available online at http://www.sciencedirect.com
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Hereditary alpha-1-antitrypsin (AT) de¢ciency is asso-
ciatedwith pulmonary emphysema of relatively early on-
set. AT is an important serum inhibitor of polymorph
elastase and in subjectshomozygous for Pi typeZ, serum
AT is only10 2^0% of the normal. Pulmonary elastin may
then be degraded by the unopposed elastase, an e¡ect
which is particularly severe in cigarette smokers (1 3^).
The abnormal Pi Z gene occurs predominantly in
those of European stock and is rare in Asian and African
populations. The gene frequency is highest in North-Received 8 April 2002, accepted 8 April 2002
Correspondence should be addressed to:Dr D.C. S.Hutchison,
Department of Respiratory Medicine, King’s College Hospital, London
SE5 9RS,U.K.Fax: +44 20 7346 3589Western Europe (4).Theprevalence of the typeZhomo-
zygote in the U.K. is about1in 3000 and is rather similar
in U.S. subjects of European origin.
This prospective study was intended ¢rstly to estab-
lish the rate of decline in lung function over a period of
some years and to assess the in£uence of smoking and
other factors on prognosis. Family data were obtained
to remove the bias imposed by the study of chest clinic
patients alone. A further objectivewas to create a regis-
ter of AT-de¢cient subjects to be used in a future trial of
AT-replacement therapy. The only randomised con-
trolled trial to date, however, (5) has shown no e¡ect
on lung function deterioration, while non-randomised
trials have had serious drawbacks (6).We consider that
further recommendations on the conduct of future clin-
ical trials are appropriate and necessary at the present
time.
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Case selection
Blood samples from patients suspected of AT de¢ciency
were submitted by specialists in respiratorymedicine to
the MRC Human Biochemical Genetics Unit, University
College, London or to the Supra-Regional Protein Refer-
ence Laboratory, She⁄eld. Pi type was initially assessed
by starch gel electrophoresis (7,8) and all Pi Z samples
were subsequently checked by isoelectric focusing
(IEF) (9).
This report is limited to subjects homozygous for Pi
type Z. The term Pi Z refers to subjects apparently
homozygous for type Z but where the ’Null’ gene has
not been excluded (10); this applies to the majority of
subjects in this survey.
Patients identi¢ed through attendance at respiratory
medicine clinics were classi¢ed as ‘Index cases’. Blood
sampleswere requested from all full brothers and sisters
(the ‘sibs’) of the index cases; Pi Z subjects so identi¢ed
were classi¢ed as ‘non-index’ cases. Patients were en-
rolled over a 10 year period and follow up continued
yearly for a further 5 years.
Patients under 20 years of age, who had undergone
thoracic surgery or had other life-threatening diseases,
were excluded from the study.
Patient assessment
Patients were assessed by means of a modi¢ed MRC
questionnaire (11) administered at approximately yearly
intervals. Details were obtained on grade of dyspnoea
and of bronchitis, the amount and type of smoking, the
presence of asthma and other disease and occupational
exposure to dust or fumes. Initial results obtainedby this
method have already been reported (3,12).
Smoking history
Details of smoking were obtained at each assessment.
Any subject who had smoked at least one cigarette per
day (whethermanufactured or hand-rolled) for1year or
more was classi¢ed as a cigarette smoker. The ages of
starting and stopping smoking were recorded.The total
tobacco consumption over the patient’s life was esti-
mated and expressed in kilograms (kg) (one kg equals
7.3 pack-years). Patients who had smoked only pipe or ci-
gars, but never cigarettes were excluded from the study.
Smoking status
Patients were divided into three groups:
(a) ‘Current smokers’: smoking cigarettes as de¢ned
above at the time of any assessment, even if they
had stopped at a later assessment.(b) ‘Ex-smokers’: had smoked cigarettes in the past but
had stopped before the ¢rst assessment and did not
smoke thereafter.
(c) ‘Never Smokers’: hadnever smoked cigarettes, pipe or
cigars and did not smoke at the time of any
assessment.
Asthma
The opinion of the patient’s physician on the presence or
absence of asthmawas recorded.
Lung function tests
Tests were performed in each subject at the laboratory
of choice. Forced expiratory volume in 1sec (FEV1) and
relaxed vital capacity (VC) were measured before ad-
ministration of inhaled bronchodilator and in most
assessments repeated after the bronchodilator. Bronch-
odilator was administered as two pu¡s of salbutamol
from ametred dose inhaler.The best of three technically
acceptable resultswas recorded and the resultswere ex-
pressed as a percentage of normal reference (or ‘pre-
dicted’) values (%P) (13).
In the follow-up study, the post-bronchodilator test
was omitted in 153 out of 569 FEV1 measurements.
Where this testwas omitted, FEV1waso40% P in 83 in-
stances (54%) ando90% P in 29 (19%).Therefore, to ob-
tain the mean FEV1%P and VC%P for any group and for
the individual rates of decline (or ‘slopes’), the FEV1 and
VC at any time point were taken as the highest of the
available pre-and post-bronchodilator values (see Dis-
cussion for justi¢cation of this procedure).
Standards for lung function
Testswereperformed according to the1965 guidelines of
the U.K. Medical Research Council (11) and subsequent
European standards (13).The Association of Respiratory
Technicians and Physiologists (ARTP) (founded as U.K.
national body in 1975) were and remain responsible for
the education and training of laboratory sta¡ (14). In
U.K. lung function laboratories 62% used a plastic bel-
lows spirometer and 24% a rolling seal spirometer.
The ‘Follow-up’group
The regression coe⁄cients of FEV1and VC on time (FEV1
and VC slope) were obtained for each subject who had
six or more assessments spanning a total of at least 4
years.The FEV1 slopes were standardised as follows: for
each patient, the FEV1and VC slopeswere dividedby the
appropriate FEV1 or VC reference value (13) at registra-
tion, to obtain the ‘standardized slope’ expressed as
%predicted/year.
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1. Homozygous for Pi type Z, veri¢ed by IEF.
2. Smoking status established as described above.
3. Lung function tests including FEV1%P available at start
of study and at all follow-up assessments.
Statistics
The data were processed using the SPSS statistical pack-
age (15). The rates of change in lung function indices for
each patient were obtained by regression analysis over
time, using a linear regression model. The regression
coe⁄cients (expressed as ml/year or ml/year %P) were
compared between groups by the unpaired t-test.Values
of Po0.05 were considered as statistically signi¢cant.
Multiple regression analysis with FEV1%P as the depen-
dent variable was carried out to assess the e¡ects of ci-
garette smoking history, amount smoked (kg), age of
starting to smoke, inhalation habit, asthma, gender, age
of entry and occupational exposure to dust or fumes.
Analysis of variancewas used for the family study.
RESULTS
A total of 242 Pi Z subjects were identi¢ed during the
enrolment period. In 42 (17.4%) cases, lung function tests
were incomplete or not available.Of these,17 were too
old or disabled to attend the lung function laboratory;
otherwise, no de¢nite reason was established. Six pa-
tientshad smokedonlypipe or cigars andwere therefore
excluded from the study.
Results are presented in two parts: Baseline study
(data at registration); Follow-up study.TABLE 1. Baseline study; age,FEV1%P
a & VC%Pa atentryby smo
N (%) Age atentry
mean S
All cases 194 (100) 48.8 10
N-Sm 39 (20) 54.1 13
Ex-Sm 115 (59) 48.8 9
Curr-Sm 40 (21) 43.7 9
Values of P Age
N-Sm vs Ex-Sm o0.05
N-Sm vsCurr-Sm o0.001
Ex-Sm vsCurr-Sm o0.005
aBestof pre- andpost-bronchodilator values.
NS:P4 0.05.
N-Sm: never smokers;Ex-Sm: ex-smokers;Curr-Sm: current smBaseline Study
E¡ects ofcigarette smoking
Onehundred andninety-four patients ful¢lled the criter-
ia for inclusion in the baseline study (Table 1). One hun-
dred and ¢fty-¢ve (80%) were classi¢ed as ‘cigarette
smokers’, 40 (21%) being ‘current smokers’ and 115 (59%)
being ‘ex-smokers’. One hundred and forty-three had
smoked only manufactured cigarettes, four had smoked
only hand-rolled cigarettes, and eight had smoked both
types at some time.The remaining 39 (20%) were ‘never
smokers’.
At entry to the study, never smokers were signi¢-
cantly older than ex-smokers (Po0.05) whowere signi¢-
cantly older than current smokers (Po0.005).
Never smokers had a signi¢cantly highermean FEV1%P
(Po0.001) than both ex- and current smokers.FEV1%P in
all three groups was very signi¢cantly below 100% P
(Po0.001).
VC%P in never smokerswas not signi¢cantlydi¡erent
from normal; in both smoking groupsVC %P was signi¢-
cantly below 100 %P (Ex-smokers Po0.001: Current
Smokers Po0.01).
Multiple regression analysis
This was carried out in two stages with FEV1%P as the
dependent variable.
Stage1: All194 eligible cases in the baseline study.
Low values of FEV1%P were signi¢cantly related to a
history of cigarette smoking (Po0.0001), age of entry (P
= 0.0009) andmale gender (P = 0.021).Other factors en-
teredbut not signi¢cant (P4 0.1) were asthma and occu-
pational exposure to dust or fumes.
Stage 2: All 143 cases who had smoked manufactured
cigarettes, but no other smokingmaterials.king status
FEV1%P
a VC %P a
D mean SD mean SD
.8 44.5 26.8 85.6 27.2
.8 67.4 31.6 94.5 24.6
.2 36.5 22.0 81.8 27.6
.7 45.0 21.2 87.7 26.6
FEV1% P
a VC%Pa
o0.001 o0.01
o0.001 NS
o0.05 o0.05
okers.
ALPHA-I-ANTITRYPSINDEFICIENCY 875The relationship between FEV1%P and the smoke inha-
lation habit did not reach a signi¢cant level (P = 0.082).
Other factors enteredbut not signi¢cant (P4 0.1) were:
gender, age of entry, amount smoked (kg), age of starting
to smoke, asthma, occupational exposure to dust or
fumes.
FOLLOW-UP STUDY
There were 71 patients in the follow-up group, who, by
de¢nition, had six or more assessments of FEV1%P over
a period of at least 4 years.Their mean age at entry was
46.9 years (SD 8.6; range 21 7^1). The average number of
assessments per patient was 8.0 (range 6 1^3). The aver-
age follow-up time span was 9.7 years (range 4.2 1^4.9).
Values for the FEV1%P and VC%P at entry and for the
rate of decline in FEV1and VC (inml/year and as per cent
of predicted) in various groups are shown inTables 2 and
3 and in Fig1.
Index and non-index cases: FEV1%P was very much
greater in the non-index cases (Po0.001); there was noTABLE 2. Follow-up group: Indexcases, smoking groups and st
Group N FEV1%P
a
Mean SD
All cases 71 55.3 28
Index 52 44.4 19
Non-index 19 85.0 29
N-Sm 13 83.6 22
Ex-Sm 44 47.7 26
Curr-Sm 14 52.9 21
Strati¢ed by FEV1%P
o30 14 F F
30 6^5 34 F F
465 23 F F
FEV1%P
Values of P
Index vs Non-Index o0.001
N-Smvs Ex-Sm o0.001
N-Smvs Curr-Sm o0.005
Curr- vs Ex-Sm NS
FEV1%P
o30 vs. 30 6^5 F
30 6^5 vs465 F
NS:P40.05.
N-Sm: never smokers;Ex-Sm: ex-smokers;Curr-Sm: current sm
aBestof pre- andpost-bronchodilator values.
bStandardised slope (%P/year) = FEV1slope (ml/year) 100/predsigni¢cant di¡erencebetween the two groups in therate
of decline in FEV1%P.
E¡ects of smoking
Of the 71 follow-up patients, 81.7% had smoked (com-
binedex-smokers andcurrent smokers) a similar propor-
tion (79.9%) to the baseline group of 194. There was no
signi¢cant di¡erence between the three smoking-de-
¢ned groups in age at enrolment or in length of follow
up (subjects who had smoked only pipes or cigars were
excluded from the analysis).
FEV1%P (Table 2 and Fig.1) was very signi¢cantly lower
in smokers than in never-smokers.For therate of decline
in FEV1%P, there was no di¡erence between never smo-
kers and current smokers; ex-smokers had a lower rate
of decline than never smokers or current smokers.
E¡ect of smoking onVC %P (Table 3 and Fig.1): there
was no di¡erence between the three smoking de¢ned
groups in VC% P at entry. The rate of decline in VC (as
ml/year or %P/year) was very signi¢cantly lower in never
smokers than in ex-smokers.rati¢cation
FEV1slopes
a
ml/year %P/yearb
Mean SD Mean SD
.4 66.3 46.3 2.01 1.35
.0 64.8 49.1 1.92 1.41
.1 70.3 38.5 2.28 1.17
.8 80.5 45.7 2.49 1.10
.8 55.4 43.4 1.70 1.32
.8 87.2 47.8 2.55 1.44
21.1 24.0 0.57 0.72
72.9 41.3 2.17 1.26
84.0 47.1 2.66 1.15
FEV1slope
a
ml/year %P/yearb
NS NS
NS NS
NS NS
o0.05 NS
o0.001 o0.001
NS NS
okers.
icted FEV1 (ml).
TABLE 3. Follow-up cases;VC %P (baseline) and VCSlope by Smoking Status
Group N VC%Pa VC slopea
ml/yeara %P/yearb
Mean SD Mean SD Mean SD
All cases 71 96.0 24.9 99.2 97.8 2.51 2.42
N-Sm 13 100.4 17.4 49.5 49.5 1.40 1.40
Ex-Sm 44 95.8 26.6 105.4 90.1 2.71 2.26
Curr-Sm 14 92.4 26.2 125.9 137.8 2.93 3.34
Values of P
N-Sm vs Ex-Sm NS o0.01 o0.01
N-Sm vsCurr-Sm NS NS NS
Curr-Sm vs Ex-Sm NS NS NS
NS:P40.05.
N-Sm: never smokers;Ex-Sm: ex-smokers.Curr-Sm: current smokers.
aBestof pre- andpost-bronchdilator values.
bStandardised slope (%P/year) = VCSlope (ml/year) 100/predicted VC (ml).
FIG. 1. Mean slopes of FEV1% P (continuous lines) and VC %P
(dashed lines) in the 71 follow-up cases (never, ex- and current
smokers).
876 RESPIRATORYMEDICINEStrati¢cation by FEV1%P (Table 2)
The rate of decline in FEV1 (ml/year or %P) was very sig-
ni¢cantly greater in those with FEV1 430%P than in
those with FEV1o30 %P.There was no signi¢cant di¡er-
ence between the three groups in age at entry or in
length of follow up.
E¡ect of number ofassessments on FEV1Slopes
For the 71follow-up cases, the FEV1slopeswere recalcu-
lated using only the ¢rst four assessments. The mean
slopewas59.6ml/year (SD 90.2) or 6.7ml/year less steep
than thevaluebased on all assessments (Table 2).This dif-
ference is not signi¢cant (paired t-test), but the variance
in the‘four assessment’groupwas signi¢cantly greater (F
= 3.79:Po0.01).E¡ect of bronchodilator on FEV1and VC Slopes
From the 71 follow-up cases, 18 were selected with at
least ¢ve assessments of FEV1 and VC with paired pre-
and post-bronchodilator values (Table 4). Both FEV1 and
VC have on an average faster rates of decline after
bronchodilator, though there is a wide range in both
(paired t-test: not signi¢cant). The average bronchodila-
tor response therefore becomes smaller with the pas-
sage of time.
Within family trends
Thirty-one families with paired sibs all homozygous for
Pi type Zwere examined. These consisted of the index
case and the ¢rst subsequent sib to be ascertained. Ana-
lysis of variance using the 18 families with sib pairs con-
cordant for smoking revealed no signi¢cant di¡erence
between the ‘within family’ and the ‘between family’ var-
iances of FEV1%P.
Non-follow-up cases
There were 123 patients who had less than six assess-
ments and thus did not qualify for the follow-up group.
Theirmean age at entry was 49.9 year (SD11.8), not signif-
icantly di¡erent from the follow-up group. Their mean
FEV1 %P on entry was 38.2 (SD 23.8), signi¢cantly less
than that of the follow-up group (Po0.001).
DISCUSSION
The ¢ndings from the baseline section of this study are
similar to those reported in the original description of
TABLE 4. Slopes of FEV1and VC (ml/year) before and after bronchodilator
Mean SD Range
FEV1slope
Before bd 55.9 53.2 183 to +25
After bd 62.0 48.3 160 to1
Di¡erence 6.1 23 (P4 0.05)
VC slope
Before bd 81.5 86.5 209 to +122
After bd 98.6 81.3 247 to +32
Di¡erence 17.1 60 (P4 0.05)
bd: bronchodilator.
P: for paired t-test.
ALPHA-I-ANTITRYPSINDEFICIENCY 877the disease (1) and in previous studies (2,3,12,16). The
poor lung function of index cases and the serious e¡ects
of smoking are widely recognised. The non-index cases,
who are detected through family studies rather than by
presentation at a chest clinic are generally much less se-
verely a¡ected than the index cases (3).There are never-
theless wide variations in both smokers and non-
smokers, many of the latter having normal lung function
and a normal life span.
(Analysis of smoking e¡ects in this study are based
mainly on the presence or absence of a smoking history.
This shows a much stronger relationship with lung func-
tion than thememories of past tobacco consumption or
inhalation habit which are likely to be less reliable.)
E¡ects of smoking history on FEV1and VC
slopes
There are considerable di¡erences between the mean
FEV1 slopes obtained in previous studies (12,16 1^9), but
wide standarddeviations are seen in all. In a commonpat-
tern, the FEV1slopes were less steep in ex-smokers than
in never or current smokers as in thepresent study.VC is
seldom reported in follow-up studies; in this study, VC
%P remained at over 90 %P even where FEV %P was se-
verely impaired as in current and ex-smokers (Table 3
and Fig.1). TheVC slopes were less steep in never smo-
kers than in those who had smoked. The FEV1 and VC
slopes are here also presented in a ‘standardised’ form,
where the individual slopes are divided by the appropri-
ate reference value at registration, the rationale being
that a given slope (e.g. 50ml/year) would have the great-
est impact in persons with the smallest reference values.
It is natural to hope for an improvement in prognosis
when patients give up smoking and in this (Table 2) and
other studies (17,19), a comparison of the rates of decline
in FEV1in current andex-smokers suggests that this does
occur to a modest extent. Likewise in non-AT de¢cientforms of emphysema, the FEV1 slope is signi¢cantly less
steep in patients who give up smoking (20,21). Unfortu-
nately, many patients abandon the habit at such a late
stage that little bene¢t is achieved.
The role of smoking canbemore readily understood if
the twovariables, FEV1%P and FEV1slope are considered
together as in Fig. 1. It is clear that those who have
smoked (including both current and ex-smokers) have
by the mid-forties age range, deteriorated far more ra-
pidly that thosewho have never smoked; by this age the
FEV1 slope in the ex-smokers is little di¡erent from that
of the current smokers.
The rapid deterioration in thosewith intermediate le-
vels of lung function is con¢rmed inTable 2 (strati¢cation
section) and in previous studies (12,22,23). In the present
study, the earliest age of starting to smoke was 8 years;
in some who started so young, lung function may never
have achieved itsmaximumpotential.
Even when the e¡ects of smoking have been elimi-
nated, wide and unexplained di¡erences are observed in
the outcome and prognosis of subjects with AT de¢-
ciency. Asthma and atopy were reported to be com-
moner in AT-de¢cient patients than in non-AT related
COPD (24), though in the present study asthma had no
e¡ect on outcome, possibly because this group smoked
less. Other possible genetic disorders have been sug-
gested (25), though none appear to account for any but
a small proportion of the observed cases of emphysema.
In the present study, analysis of variance in a small num-
ber of sib pairs did not demonstrate any such ‘intra-fa-
mily’ factor.
Alpha-1-antitrypsin replacement therapy
The wide variations in outcome are also relevant to the
planning of therapeutic trials in AT de¢ciency. Potentially
suitable intravenous replacement therapy has been avail-
able for many years andwith reasonable safety can raise
878 RESPIRATORYMEDICINEthe serumAT concentration of de¢cient subjects to nor-
mal levels (26).
It has been claimed in two separate non-randomised
trials that such therapy can reduce the rate of decline in
lung function (22,23). Both of these trials had serious
drawbacks (6), and the only randomised controlled trial
to date (5) has shown that the therapy had no signi¢cant
in£uence on the decline in anymeasure of lung function,
though there was a just discernible, but not signi¢cant
advantage (P = 0.07) in terms of lung density measured
by CT scanning. This result is of interest, though one
might expect replacement therapy worthy of the name
to be at least as bene¢cial as the abandonment of smok-
ing, which has been shown in this and other studies (20,
21) to bring about a statistically signi¢cant reduction in
the rate of lung function decline in emphysema.
This concept is illustrated in a model situation based
on a linear change in FEV1 (Figs. 2(A) and 2(B)). Assuming
thatdeath occurswhen FEV1falls to 0.3 l (10% P), then Fig.
2(A) indicates that fully e¡ective treatment starting at
the age of 30 would lead to an extra 20 or more years of
life and starting at age 50, to an extra 10 years. Figure
2(B), on the other hand, shows that less e¡ective treat-
ment starting at the age of 30, would reduce the addi-
tional life expectancy to an extra 10 years and starting
at 50, to an extra 3 years only. This model implies that,
to be useful, replacement therapy should be given at an
early stage of the disease, before the onset of sympto-
matic emphysema.
An ideal study would thus include a high proportion of
Pi Z subjects without severe clinical emphysema. A
screening procedure would be necessary, but most
methodshave serious drawbacks.Byrandomisedpopula-
tion screening, the prevalence of Pi type ZZ subjects in
North-Western Europe is about1in 2000, butmay be asFIG. 2. Theoreticalmodelof ATreplacementtherapy: dashedline
60ml/year, startingat FEV1of 2.1lor 70%P.Continuouslines: after tr
30m/year. (B)-treatmentresults in a half-waycorrectionofthe FEV1
untreated case and after commencementof treatment at age 50 andlow as1in10 000 in parts of Southern Europe (4). Among
relatives of index cases, it is only worth testing the full
sibs; it can be shown however that only a small minority
of sibs are likely to be of type ZZ, though among them
would be a proportion with well-preserved lung func-
tion.
The World Health Organisation’s recommendation
(27) of screening all adolescent asthmatics is likely to as-
certain ZZ subjects only at the local population fre-
quency, since there is no proven link between the two
conditions. A study of patients selected for radiological
emphysema (28) revealed that 13% were of type ZZ,
but the present study suggests that, themajority of such
patients would have di⁄culty in completing a controlled
trial of several years duration.
Length of follow-up andnumber of
assessments
The variance of FEV1slopes obtained in the group based
on four assessments alone (i.e. 3 years) was signi¢cantly
greater (F = 3.79:Po0.01) thanwhen based on all assess-
ments, reducing the likelihood of detecting any change in
slope produced by the therapy. In a longitudinal study
(29) in non-AT de¢cient COPD, there was an actual in-
crease in FEV1 in the ¢rst 6 months before a subsequent
decline, precluding the use of linear regression incorpor-
ating the initial data points. It follows that regression
coe⁄cients based on just two lung function assessments
1year apart would be unreliable (17,19).Trials should thus
be based on assessments at intervals of notmore than1
year over the trial period and a run-in period appears
necessary, perhaps for 6 months.(A & B): untreatedrate ofdecline in FEV1over a 30-yearperiod at
eatment. (A)-treatmentreducesrate ofdecline to a normalrate of
slope to 45ml/year.Points A^C: age of arrival at FEV1% P= 10% in
30 years, respectively.
ALPHA-I-ANTITRYPSINDEFICIENCY 879Bronchodilator response
In those studies in which serial change in FEV1 has been
assessed, little or no attentionhasbeenpaid to theuse of
bronchodilator; in one study, only pre-bronchodilator
results were included (19) and in others (16 1^8) the mat-
ter was not addressed. In the present study, post-
bronchodilator assessment was omitted in 27% of in-
stances mainly in patients whose lung function was
either normal or highly abnormal. Bronchodilator has lit-
tle e¡ect on FEV1at these levels (30), and we considered
that, in default, the best available result should be used.
In defence of this procedure, it is a common experi-
ence that, even if asked to refrain, patients with ad-
vanced disease are often obliged to use a bronchodilator
simply in order to travel to the laboratory.Furthermore,
patients taking oral or nebulised therapy are seldom
likely to be in a true‘pre-bronchodilator’ state.This argu-
ment is rather less sound in the assessment of VCwhere
substantial increases are observed after bronchodilator
in emphysema (3,30), and thus carbonmonoxide transfer
factor and static lung volumes would also be a¡ected.
The FEV1and VC slopes are both rather steeper after
bronchodilator administration (Table 4), though the dif-
ferenceswerenot signi¢cant in the small sample available
for testing. Post-bronchodilator results are less subject
to variations in bronchomotor tone andmore consistent
results shouldbe obtained aftermaximal bronchodilator
therapy.
Conclusions
Only randomised controlled trials will be acceptable in
the future (6), and their results could bemademore reli-
able by the followingmeasures:
(A) Selection: A trial should avoid subjects with FEV1
lower than 40% P. Patients with low FEV1aremore likely
to withdraw; a drop-out rate of 46% was noted over a 3
year period in a study inwhich themean FEV1was 50% P
on entry (29). Ideally, selection should include a high pro-
portion of Pi Z subjects without clinical emphysema,
though the necessary screening procedures raise a num-
ber of problems. Symptomless subjects with normal or
near normal FEV1 should be selected only if shown to
have an excessively high rate of decline in lung function.
All should be current non-smokers veri¢ed by a bio-
chemicalmarker such as urinary cotinine.
(B) Standardisation of lung function testing:This is essen-
tial and should now be well established in Europe and
North America, the areas where such trials are likely to
take place (13). FEV1,VC and a number of other common
lung function indices are in£uencedbymostbronchodila-
tors.We recommend thatmaximal bronchodilator ther-
apy should be used as the standard for future clinical
trials.(C)Numbers andlength ofstudy:Thenumbers required
for a clinical trial have been calculated by a number of
authors (18,31), but remain somewhat arbitrary, as the
total depends on theprecise conditions selected. Investi-
gators shouldprobably aim for not less than 250 patients
in each arm of a study of at least six assessments at
yearly intervals; regression coe⁄cients are less reliable
in shorter studies. A run-in period is also desirable.
(D) Serialmeasurementof lungdensitybyCTscanning
shouldbe done at yearly intervals provided that all parti-
cipating centres observe identicalmethodology.
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